Literature DB >> 9191432

Percutaneous microwave coagulation therapy in liver tumors. A 3-year experience.

T Matsukawa1, Y Yamashita, A Arakawa, T Nishiharu, J Urata, R Murakami, M Takahashi, S Yoshimatsu.   

Abstract

PURPOSE: Percutaneous microwave coagulation therapy (PMCT) is an interventional alternative for inoperable malignant liver tumors. In this paper, we report the results of our 3-year experience of PMCT in order to establish suitable indications for this treatment.
MATERIAL AND METHODS: We studied a total of 27 inoperable liver tumors in 24 patients. Histology of the tumors showed 20 hepatocellular carcinomas (HCCs) (13 well differentiated, 4 moderately differentiated, and 3 poorly differentiated) and 7 metastases. These tumors were treated by PMCT and were followed for 4-40 months (average 18 months). Under US guidance, the tumors were coagulated by microwaves emitted from an electrode. The changes of tumor size after PMCT were evaluated by CT. When the tumors disappeared or were reduced in size after treatment, PMCT was regarded as effective. Complications from PMCT were also evaluated. The patient survival rate was obtained by means of the Kaplan-Meier method.
RESULTS: In tumors of 30 mm or less, treatment response was obtained in 70% of cases, while 55% of tumors larger than 30 mm responded. The tumor became smaller or disappeared in 85% of the well differentiated HCCs, and in 25% of the moderately differentiated HCCs, but none of the poorly differentiated HCCs responded. In metastatic tumors, PMCT was effective in 57% of cases. Slight pain (24%), fever (20%) and subcutaneous hematoma (8%) were experienced immediately after PMCT. In 2 poorly differentiated HCCs, needle tract seeding was observed. No case of liver dysfunction was seen after PMCT. The overall survival rate was 83.1% at 1 year and 68.7% at 2 years.
CONCLUSION: Good therapeutic results were achieved with PMCT in lesions of 30 mm or less, and in well differentiated HCCs.

Entities:  

Mesh:

Year:  1997        PMID: 9191432     DOI: 10.1080/02841859709172092

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  12 in total

Review 1.  Microwave ablation of hepatocellular carcinoma.

Authors:  Guido Poggi; Nevio Tosoratti; Benedetta Montagna; Chiara Picchi
Journal:  World J Hepatol       Date:  2015-11-08

2.  Disruption of erythrocytes distinguishes fixed cells/tissues from viable cells/tissues following microwave coagulation therapy.

Authors:  Tsuyoshi Yamaguchi; Ken-Ichi Mukaisho; Hiroshi Yamamoto; Hisanori Shiomi; Yoshimasa Kurumi; Hiroyuki Sugihara; Tohru Tani
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

3.  Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study.

Authors:  Ming-De Lu; Hui-Xiong Xu; Xiao-Yan Xie; Xiao-Yu Yin; Jun-Wei Chen; Ming Kuang; Zuo-Feng Xu; Guang-Jian Liu; Yan-Lin Zheng
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 7.527

4.  Percutaneous microwave ablation of liver cancer adjacent to the gastrointestinal tract.

Authors:  Pei Zhou; Ping Liang; Xiaoling Yu; Yang Wang; Baowei Dong
Journal:  J Gastrointest Surg       Date:  2008-09-30       Impact factor: 3.452

5.  Microwave coagulation using a perfusion microwave electrode: Preliminary experimental study using ex vivo and in vivo liver.

Authors:  Hideto Umehara; Toshihito Seki; Ryosuke Inokuchi; Toru Tamai; Rinako Kawamura; Toshiki Asayama; Kozo Ikeda; Kazuichi Okazaki
Journal:  Exp Ther Med       Date:  2011-11-11       Impact factor: 2.447

Review 6.  Interventional therapies of unresectable liver metastases.

Authors:  Jun Qian
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-11       Impact factor: 4.553

Review 7.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

8.  Intra-operative microwave ablation of liver malignancies with tumour permittivity feedback control: a prospective ablate and resect study.

Authors:  Linda Ratanaprasatporn; Kevin P Charpentier; Murray Resnick; Shaolei Lu; Damian Dupuy
Journal:  HPB (Oxford)       Date:  2013-03-29       Impact factor: 3.647

9.  Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma.

Authors:  Chung-Bao Hsieh; Hao-Ming Chang; Teng-Wei Chen; Chung-Jueng Chen; De-Chuan Chan; Jyh-Cherng Yu; Yao-Chi Liu; Tzu-Ming Chang; Kuo-Liang Shen
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

Review 10.  Surgical therapy for colorectal metastases to the liver.

Authors:  Timothy M Pawlik; Michael A Choti
Journal:  J Gastrointest Surg       Date:  2007-08       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.